Program
HRS-9813
A development code. Also written as “HRS-9813 Capsule”, “HRS-9813 capsules” and “HRS-6209 in Combination with HRS-9813 and Letrozole”.
Its studies are mostly in Pulmonary Fibrosis · Breast Neoplasms · Idiopathic Pulmonary Fibrosis, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 62 open or running | phase 2since Aug 1, 2024 | Jul 17, 2024 | Dec 2027phase 2 · NCT06555068 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-9813
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 17, 2024First study: phase 1 study in Healthy VolunteersFirst studyNCT06514963 · 50 enrolled · China
- Aug 1, 2024Phase 2 study in Breast NeoplasmsNCT06555068 · 528 planned · China
- Feb 5, 2025Phase 1 study in Idiopathic Pulmonary FibrosisNCT06821464 · 45 enrolled · China
- Apr 15, 2025Phase 1 study in Pulmonary FibrosisNCT06939504 · 12 enrolled · China
- Sep 18, 2025Phase 2 study in IPF and PPFNCT07192939 · 270 planned · China
- Nov 13, 2025Phase 1 study in Pulmonary FibrosisNCT07229716 · 20 enrolled · China
Ahead
- Dec 2027Primary completion: phase 2 study in Breast NeoplasmsNCT06555068
- Jun 2028Primary completion: phase 2 study in IPF and PPFNCT07192939
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07229716Pulmonary Fibrosis · China | 1 | Completed | Jun 18, 2026 | 20 |
| NCT07192939IPF and PPF · China | 2 | Recruiting | Jun 2028 | 270 |
| NCT06939504Pulmonary Fibrosis · China | 1 | Completed | Jun 3, 2025 | 12 |
| NCT06821464Idiopathic Pulmonary Fibrosis · China | 1 | Completed | Jul 27, 2025 | 45 |
| NCT06555068Breast Neoplasms · China | 2 | Recruiting | Dec 2027 | 528 |
| NCT06514963Healthy Volunteers · China | 1 | Completed | Jan 2, 2025 | 50 |
How it is read
Names in the registry
- “HRS-9813”, 3 entries
- “HRS-9813 Capsule”, 2 entries
- “HRS-9813 capsules”, 2 entries
- “HRS-6209 in Combination with HRS-9813 and Letrozole”, 1 entry
- “HRS-6209 in Combination with HRS-9813 and HRS-8080”, 1 entry
Codes read as this program: HRS9813.
Conditions, from the studies’ own filings
- Pulmonary Fibrosis, 2 studies
- Breast Neoplasms, 1 study
- Idiopathic Pulmonary Fibrosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.